“Musculoskeletal Pain Treatment Market”
Musculoskeletal pain companies such as Virios Therapeutics, Mesoblast, Regeneron, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Sorrento Therapeutics, Taiwan Liposome Company, Eli Lilly and Company, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals,Propella Therapeutics, Novartis, Moebius Medical, Antibe Therapeutics,Tonix Pharmaceuticals, ACADIA Pharmaceuticals, AstraZeneca, and others
(Albany, USA) DelveInsight’s Musculoskeletal Pain Market Insights report includes a comprehensive understanding of current treatment practices, musculoskeletal pain emerging drugs, market share of individual therapies, and current and forecasted musculoskeletal pain market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Musculoskeletal Pain Market Report
- As per DelveInsight’s analysis, among 7MM, the United States accounts for the highest musculoskeletal pain market size in 2023 with nearly USD 3295 million.
- As per DelveInsight estimates, the total 7MM diagnosed prevalent cases of musculoskeletal pain in 2021 were over 146 million, out of which the highest cases were observed in the United States.
- Leading musculoskeletal pain companies such as Virios Therapeutics, Mesoblast, Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Sorrento Therapeutics, Taiwan Liposome Company, Eli Lilly and Company, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Techfields Pharma, Camurus, Braeburn Pharmaceuticals, Kolon TissueGene, Amzell, Seikagaku Corporation, Teva Pharmaceutical Industries, Propella Therapeutics, Novartis Pharmaceuticals, Sun Pharmaceutical Industries, Moebius Medical, Antibe Therapeutics, Aesculap Biologics, VivaTech, Xalud Therapeutics, Tonix Pharmaceuticals, ACADIA Pharmaceuticals, AstraZeneca, Charleston Laboratories, and others are developing novel musculoskeletal pain drugs that can be available in the musculoskeletal pain market in the coming years.
- Some of the key therapies for musculoskeletal pain treatment include Rexlemestrocel-L (MPC-06-ID), Fasinumab, Resiniferatoxin, TLC599, LY3556050, LY3016859, Esreboxetine (AXS-14), Lorecivivint, CNTX-4975, Ampion, X0002, IMC-1, Buprenorphine/CAM2038, TG-C/INVOSSA/Tonogenchoncel-L, AMZ001, Joyclu, Fremanezumab, CGS-200-5, DFV890, Canakinumab, MM-II, Otenaproxesul/ATB-346, NOVOCART 3D, StroMed + platelet-rich plasma (PRP), XT-150, TNX-102 SL, ACP-044, MEDI7352, CL-108, and others.
- In February 2023, Mesoblast announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as a delivery agent for injection into the lumbar disc.
Discover which therapies are expected to grab the major musculoskeletal pain market share @ Musculoskeletal Pain Market Report
Musculoskeletal Pain Overview
Musculoskeletal pain refers to persistent or recurrent pain affecting the bones, muscles, ligaments, tendons, and nerves. Pain associated with musculoskeletal (MSK) disorders is a prevalent issue with significant medical and socioeconomic implications worldwide. Chronic musculoskeletal pain, notably low back pain, stands as a leading cause of global disability. According to the World Health Organization (WHO), 20–33% of the world’s population grapples with some form of chronic musculoskeletal pain, equating to approximately 1.75 billion individuals worldwide. The Pain Task Force of the International Association for the Study of Pain (IASP) defines chronic primary musculoskeletal pain (CPMP) as persistent pain in the muscles, bones, joints, or tendons, accompanied by substantial emotional distress (such as anxiety, anger, frustration, and depression) or functional impairment.
Musculoskeletal Pain Epidemiology Segmentation
The musculoskeletal pain epidemiology section provides insights into the historical and current musculoskeletal pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The musculoskeletal pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Musculoskeletal Pain Diagnosed Prevalent Cases
- Musculoskeletal Pain Gender-specific Cases
- Musculoskeletal Pain Age-specific Cases
Download the report to understand which factors are driving musculoskeletal pain epidemiology trends @ Musculoskeletal Pain Epidemiological Insights
Musculoskeletal Pain Treatment Market
Traditionally, NSAIDs were the standard approach to treating musculoskeletal pain. Existing research suggests a moderate level of evidence supporting their efficacy. Nonetheless, there is also moderate evidence indicating the effectiveness of pharmacological therapies for short-term musculoskeletal pain relief. Therefore, options like NSAIDs, Cox-2 selective inhibitors, and opioids have demonstrated the capacity to alleviate pain in the short term. However, it’s essential to recognize that the impact of these treatments is relatively modest, and potential adverse effects such as gastrointestinal bleeding and opioid-induced hyperalgesia must be approached with caution. In the market, there are several drugs available for musculoskeletal pain relief, including Zilretta, Cingal, Cymbalta, Drizalma Sprinkle, and Loqoa Tape.
Zilretta made history in October 2017 as the first and only extended-release, intra-articular therapy sanctioned by the US FDA for patients dealing with knee pain due to osteoarthritis by functioning as glucocorticoid receptor agonists. The company embarked on a full-scale commercial launch in November 2017. Although current evidence points to its effectiveness in providing short-term relief for shoulder and knee pain, its impact on back and neck pain remains uncertain.
Within the realm of osteoarthritis treatment, Cingal has emerged as a game-changer, securing approval in the European Union due to its remarkable effectiveness in managing associated pain. This groundbreaking medication is composed of FDA-approved triamcinolone hexacetonide, a powerful anti-inflammatory steroid, and cross-linked sodium hyaluronate. It is administered through intra-articular injection, acting as a potent glucocorticoid receptor agonist. Cingal’s simplicity shines through with its single-dose preparation, with the recommended dose set at 4 mL (equivalent to one syringe) per knee joint.
Learn more about the FDA-approved drugs for musculoskeletal pain @ Drugs for Musculoskeletal Pain Treatment
Key Musculoskeletal Pain Therapies and Companies
- Rexlemestrocel-L (MPC-06-ID): Mesoblast
- Fasinumab: Regeneron Pharmaceuticals|Teva Pharmaceutical Industries|Mitsubishi Tanabe Pharma
- Resiniferatoxin: Sorrento Therapeutics
- TLC599: Taiwan Liposome Company
- LY3556050: Eli Lilly and Company
- LY3016859: Eli Lilly and Company
- Esreboxetine (AXS-14): Axsome Therapeutics
- Lorecivivint: Biosplice Therapeutics
- CNTX-4975: Centrexion Therapeutics
- Ampion: Ampio Pharmaceuticals
- X0002: Techfields Pharma
- IMC-1: Virios Therapeutics
- Buprenorphine/CAM2038: Camurus/Braeburn Pharmaceuticals
- TG-C/INVOSSA/Tonogenchoncel-L: Kolon TissueGene
- AMZ001: Amzell
- Joyclu: Seikagaku Corporation
- Fremanezumab: Teva Pharmaceutical Industries
- CGS-200-5: Propella Therapeutics
- DFV890: Novartis Pharmaceuticals
- Canakinumab: Novartis Pharmaceuticals
- MM-II: Sun Pharmaceutical Industries|Moebius Medical
- Otenaproxesul/ATB-346: Antibe Therapeutics
- NOVOCART 3D: Aesculap Biologics
- StroMed + platelet-rich plasma (PRP): VivaTech
- XT-150: Xalud Therapeutics
- TNX-102 SL: Tonix Pharmaceuticals
- ACP-044: ACADIA Pharmaceuticals
- MEDI7352: AstraZeneca
- CL-108: Charleston Laboratories
To know more about musculoskeletal pain clinical trials, visit @ Musculoskeletal Pain Treatment Drugs
Musculoskeletal Pain Market Dynamics
The dynamics of the musculoskeletal pain market are expected to change in the coming years. Numerous pharmaceutical companies are continually engaged in research and innovation to develop more effective treatment approaches for addressing the unmet needs of musculoskeletal pain. The growing prevalence of musculoskeletal pain conditions, such as knee pain related to osteoarthritis, is largely driven by the aging population, and this demographic shift is expected to significantly impact the musculoskeletal pain market in the near future. This study aims to identify potential therapeutic targets and strategies aimed at enhancing the quality of life and restoring functional capabilities in individuals suffering from chronic musculoskeletal pain.
Additionally, we seek to gain insights into the transition from acute to chronic musculoskeletal pain, explore the manifestations of peripheral and central sensitization, and examine methods for their assessment. Furthermore, we emphasize the importance of robust patient education on musculoskeletal disorders and pain syndromes to enhance the overall quality of care.
Furthermore, potential therapies are being investigated for the treatment of musculoskeletal pain, and it is safe to predict that the treatment space will significantly impact the musculoskeletal pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the musculoskeletal pain market in the 7MM.
However, several factors are impeding the growth of the musculoskeletal pain market. While extensive research has been conducted over the past several decades, the root causes and underlying pathophysiology of chronic musculoskeletal pain conditions remain elusive. Presently, the available non-opioid therapies, designed to mitigate the risks of opioid dependence and abuse, provide only limited relief and are frequently associated with notable adverse effects, such as gastrointestinal complications, organ dysfunction, and even mortality.
Chronic musculoskeletal pain, particularly low back pain, stands as a leading cause of global disability. The burden of musculoskeletal pain extends beyond the affected individuals, significantly impacting patients, healthcare systems, and caregivers alike. This burden manifests in various forms, including functional impairment, emotional distress, mood disturbances, loss of independence, and diminished overall quality of life. Managing musculoskeletal pain can be especially challenging, particularly in patients with concurrent medical conditions.
Furthermore, the musculoskeletal pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the musculoskeletal pain market growth.
Scope of Musculoskeletal Pain Market
- Study Period: 2020–2034
- Musculoskeletal Pain Report Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
- Musculoskeletal Pain Market Size in 2021: USD 3.6 Billion
- Key Musculoskeletal Pain Companies: Virios Therapeutics, Mesoblast, Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Sorrento Therapeutics, Taiwan Liposome Company, Eli Lilly and Company, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Techfields Pharma, Camurus, Braeburn Pharmaceuticals, Kolon TissueGene, Amzell, Seikagaku Corporation, Teva Pharmaceutical Industries, Propella Therapeutics, Novartis Pharmaceuticals, Sun Pharmaceutical Industries, Moebius Medical, Antibe Therapeutics, Aesculap Biologics, VivaTech, Xalud Therapeutics, Tonix Pharmaceuticals, ACADIA Pharmaceuticals, AstraZeneca, Charleston Laboratories, and others
- Key Musculoskeletal Pain Therapies: Rexlemestrocel-L (MPC-06-ID), Fasinumab, Resiniferatoxin, TLC599, LY3556050, LY3016859, Esreboxetine (AXS-14), Lorecivivint, CNTX-4975, Ampion, X0002, IMC-1, Buprenorphine/CAM2038, TG-C/INVOSSA/Tonogenchoncel-L, AMZ001, Joyclu, Fremanezumab, CGS-200-5, DFV890, Canakinumab, MM-II, Otenaproxesul/ATB-346, NOVOCART 3D, StroMed + platelet-rich plasma (PRP), XT-150, TNX-102 SL, ACP-044, MEDI7352, CL-108, and others
- Therapeutic Assessment: Musculoskeletal Pain current marketed and emerging therapies
- Musculoskeletal Pain Market Dynamics: Attribute Analysis of Emerging Musculoskeletal Pain Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Musculoskeletal Pain Market Access and Reimbursement
Discover more about musculoskeletal pain drugs in development @ Musculoskeletal Pain Clinical Trials
Table of Contents
1. Musculoskeletal Pain Market Key Insights
2. Musculoskeletal Pain Market Report Introduction
3. Musculoskeletal Pain Market Overview at a Glance
4. Musculoskeletal Pain Market Executive Summary
5. Disease Background and Overview
6. Musculoskeletal Pain Treatment and Management
7. Musculoskeletal Pain Epidemiology and Patient Population
8. Patient Journey
9. Musculoskeletal Pain Marketed Drugs
10. Musculoskeletal Pain Emerging Drugs
11. Seven Major Musculoskeletal Pain Market Analysis
12. Musculoskeletal Pain Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store.php
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Musculoskeletal Pain Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight
